Pharmacological impact on loop gain properties to prevent irregular breathing

Journal of Physiology and Pharmacology

Volumn 59, Issue 1, 2008, Pages 37-45

  Kiwull Schone H F ^a   Teppema, L ^b   Wiemann, M ^c   Kalhoff, H ^d   Kiwull, P ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d Paediatric Clinic Dortmund   (Germany)

Author keywords

Acetazolamide; Closed loop gain; Control of breathing; Methazolamide; NHE3 inhibitors

Indexed keywords

ACETAZOLAMIDE; CARBON DIOXIDE; MESSENGER RNA; METHAZOLAMIDE; PROTEIN INHIBITOR; S 11654; S 8218; SODIUM PROTON EXCHANGE PROTEIN 3; SODIUM PROTON EXCHANGE PROTEIN 3 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN STEM; BREATHING DISORDER; CARBON DIOXIDE BLOOD LEVEL; CARBON DIOXIDE TENSION; CHEMOSENSITIVITY; CONTINUOUS INFUSION; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; LOW DRUG DOSE; MALE; METABOLIC RATE; NONHUMAN; RABBIT; RISK ASSESSMENT; SLEEP APNEA SYNDROME;

ACETAZOLAMIDE; ANIMALS; BLOOD GAS ANALYSIS; BRAIN STEM; CARBON DIOXIDE; CARBONIC ANHYDRASE INHIBITORS; GENE EXPRESSION REGULATION; MALE; METHAZOLAMIDE; PARTIAL PRESSURE; RABBITS; RESPIRATORY MECHANICS; RNA, MESSENGER; SLEEP APNEA SYNDROMES; SODIUM-HYDROGEN ANTIPORTER;

EID: 42049083963     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Longobardo GS, Gothe B, Goldman MD, Cherniack NS. Sleep apnea considered as a control system instability. Respir Physiol 1982; 50: 311-333.
2. Honda Y, Hayashi F, Yoshida A, Ohyabu Y, Nishibayashi Y, Kimura H. Overall "gain" of the respiratory control system in normoxic humans awake and asleep. J Appl Physiol 1983; 55: 1530-1535.
3. Khoo MCK. Determinants of ventilatory instability and variability. Respir Physiol 2000; 122: 167-182.
4. 2 below eupnoea as a determinant of ventilatory stability in sleep. J Physiol 2004; 560: 1-11.
5. Swenson ER, Leatham KL, Roach RC, Schoene RB, Mills WJ, Hackett PH. Renal carbonic anhydrase inhibition reduces high altitude sleep periodic breathing. Respir Physiol 1991; 86: 333-343.
6. Tojima H, Kunitomo F, Kimura H, Tatsumi K, Kuriyama T, Honda Y. Effects of acetazolamide in patients with the sleep apnea syndrome. Thorax 1988; 43: 113-119
7. Verbraecken J, Willemen M, De Cock W, Coen E, Van de Heyning P, De Backer W. Central sleep apnea after interrupting longterm acetazolamide therapy. Respir Physiol 1998; 112: 59-70.
8. + exchange. Adv Exp Med Biol 2006; 580: 239-244.
9. Kiwull-Schöne HF, Teppema LJ, Kiwull PJ. Low-dose acetazolamide does affect respiratory muscle function in spontaneously breathing anesthetized rabbits. Am J Resp Crit Care Med 2001; 163: 478-483.
10. 2-sensitivity by acetazolamide in anaesthetized rabbits. CEJMed 2006; 1: 356-369.
11. +-deficient rats. FASEB J 2004; 18: 760-761.
12. Tepel M, Sanner BM, Van der Giet M, Zidek W. Increased sodium-proton antiporter activity in patients with obstructive sleep apnea. J Sleep Res 2000; 9: 285-291.
13. 2 response and lowers the apneic threshold. Am J Resp Crit Care Med 2001; 164: 1303-1311.
14. Wiemann M, Frede S, Bingmann D, Kiwull P, Kiwull-Schöne H. Sodium/proton exchanger 3 in the medulla oblongata and set point of breathing control. Am J Resp Crit Care Med 2005; 172: 244-249.
15. Wiemann M, Frede S, Tschentscher F, et al. NHE3 in the human brainstem: implication for the pathogenesis of the sudden infant death syndrome (SIDS)? Adv Exp Med Biol 2008; 605: 508-513.
16. 2-Hb saturation. Adv Exp Med Biol 1997; 428: 433-438.